PatrickM.ReaganMD

PubMed

• 448 citations
  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
  Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi
  Journal of Clinical Oncology. 2020-05-13
• 20 citations
  How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies
  Patrick M. Reagan, Sattva S. Neelapu
  Journal of Clinical Oncology. 2021-01-12
• 3393 citations
  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
  Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos
  The New England Journal of Medicine. 2017-12-10

Abstracts/Posters

• PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
  Patrick M Reagan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018